We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.88%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$142M
AUM Growth
-$26.6M
(-16%)
Cap. Flow
+$8.81M
Cap. Flow % of AUM
Cap. Flow %
6.21%
Top 10 Holdings %
Top 10 Hldgs %
45.91%
Holding
93
New
28
Increased
12
Reduced
11
Closed
39
Avg Time Held
Equity + Options
0.2
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$6.21M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$5.39M |
| 3 |
Cooper Companies
COO
|
+$5.28M |
| 4 |
Boston Scientific
BSX
|
+$5.2M |
| 5 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$5.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$4.21M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.16M |
| 3 |
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
|
+$3.31M |
| 4 |
Arrowhead Research
ARWR
|
+$3.04M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$2.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.54% |
| 2 | Miscellaneous | 36.73% |
| 3 | Technology | 0.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$798B
| $14.7M | 10.35% |
+75,000
| New | +$14.3M |
2014 Q2
0 quarters
|
|
2
CALL
Viatris
VTRS
$23.3B
| $7.73M | 5.45% |
150,000
+50,000
| +50% | +$2.46M |
2014 Q1
1 quarter
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $6.69M | 4.72% |
+30,000
| New | +$6.21M |
2014 Q2
0 quarters
|
|
|
MDVN
4
DELISTED
MEDIVATION, INC.
MDVN
| $6.17M | 4.35% |
+160,000
| New | +$5.39M |
2014 Q2
0 quarters
|
|
|
5
Cooper Companies
COO
$12.1B
| $5.42M | 3.82% |
+160,000
| New | +$5.28M |
2014 Q2
0 quarters
|
|
|
6
Teva Pharmaceutical Industries Limited
TEVA
$50.1B
| $5.24M | 3.7% |
+100,000
| New | +$5.11M |
2014 Q2
0 quarters
|
|
|
7
Boston Scientific
BSX
$63.9B
| $5.11M | 3.6% |
+400,000
| New | +$5.2M |
2014 Q2
0 quarters
|
|
8
Medtronic
MDT
$132B
| $4.78M | 3.37% |
+75,000
| New | +$4.56M |
2014 Q2
0 quarters
|
|
9
Alnylam Pharmaceuticals
ALNY
$21B
| $4.74M | 3.34% |
+75,000
| New | +$4.46M |
2014 Q2
0 quarters
|
|
10
Community Health Systems
CYH
$322M
| $4.54M | 3.2% |
121,000
+24,200
| +25% | +$805K |
2013 Q4
2 quarters
|
|
11
AtriCure
ATRC
$2.94B
| $4.14M | 2.92% |
225,000
+140,000
| +165% | +$2.33M |
2014 Q1
1 quarter
|
|
12
Insmed
INSM
$25.4B
| $4M | 2.82% |
200,000
+65,000
| +48% | +$963K |
2013 Q4
2 quarters
|
|
|
BDSI
13
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $3.62M | 2.55% |
+300,000
| New | +$2.84M |
2014 Q2
0 quarters
|
|
|
SPNC
14
DELISTED
Spectranetics Corp
SPNC
| $3.26M | 2.3% |
142,600
+92,600
| +185% | +$2.15M |
2013 Q4
2 quarters
|
|
15
Bruker
BRKR
$10B
| $3.16M | 2.23% |
130,000
+40,000
| +44% | +$868K |
2013 Q4
2 quarters
|
|
|
GEVA
16
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $3.14M | 2.22% |
+30,000
| New | +$2.55M |
2014 Q2
0 quarters
|
|
|
TRNX
17
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $2.81M | 1.98% |
120,000
-10,000
| -8% | -$208K |
2013 Q4
2 quarters
|
|
|
COV
18
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $2.7M | 1.91% |
+30,000
| New | +$2.24M |
2014 Q2
0 quarters
|
|
|
ANAC
19
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $2.66M | 1.88% |
150,000
+130,000
| +650% | +$2.09M |
2014 Q1
1 quarter
|
|
20
HCA Healthcare
HCA
$105B
| $2.54M | 1.79% |
+45,000
| New | +$2.37M |
2014 Q2
0 quarters
|
|
|
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.37M | 1.67% |
10,000
+2,000
| +25% | +$527K |
2014 Q1
1 quarter
|
|
22
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
| $2.21M | 1.56% |
+175,000
| New | +$1.42M |
2014 Q2
0 quarters
|
|
23
Accuray
ARAY
$10.9M
| $2.2M | 1.55% |
6,250
-3,750
| -38% | -$1.3M |
2013 Q4
2 quarters
|
|
24
Enanta Pharmaceuticals
ENTA
$334M
| $2.15M | 1.52% |
50,000
+15,000
| +43% | +$572K |
2014 Q1
1 quarter
|
|
|
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $2.15M | 1.51% |
20,000
-5,000
| -20% | -$348K |
2014 Q1
1 quarter
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q2 2014 Portfolio in Review
As of Q2 2014, Ghost Tree Capital held 93 positions worth $142M, down 16% from $168M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Ghost Tree Capital deployed $8.81M of net new capital in Q2 2014, opening 28 new positions and adding to 12 existing holdings. Its largest new stake was Allergan plc: 30,000 shares worth $6.69M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 49% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $2.71M trimmed.
- Ghost Tree Capital's largest Q2 2014 buy was Allergan plc: 30,000 shares worth $6.69M.
- Ghost Tree Capital added most to AtriCure in Q2 2014, an estimated $2.33M increase.
- Ghost Tree Capital's biggest Q2 2014 reduction was Avadel Pharmaceuticals, cutting an estimated $2.71M.
- Ghost Tree Capital fully exited Prothena Corp in Q2 2014, selling an estimated $4.21M.
- Ghost Tree Capital's ten largest holdings make up 46% of its $142M portfolio in Q2 2014.
- Ghost Tree Capital opened 28 new positions and closed 39 in Q2 2014.
- Ghost Tree Capital's portfolio value fell 16% quarter-over-quarter to $142M.
Based on Ghost Tree Capital's 13F filing for Q2 2014, filed 14 Aug 2014.